mushroom legal status News & Updates

The FDA has published its 'new framework for psychedelic drugs' in the New England Journal of Medicine, signaling its commitment to addressing the mental health crisis with these compounds. While the agency is working to integrate these complex programs into existing regulatory frameworks and refine its industry guidance, it explicitly states that psychedelic therapies 'remain investigational.' This outlines the cautious but committed federal approach, indicating a long path before widespread commercialization.

DoubleBlind Mag Indigenous Medicines Are Inseparable From Territory Ayahuasca can't be separated from the land, community, and people who protect it. Riccardo Vitale, PhD & Miguel Evanjuanoy, Inga people 09 Sep Your weekly dose of psychedelic insights and news You

New Zealand's medicines regulator, Medsafe, has authorized two psychiatrists to prescribe and administer MDMA for PTSD, building on last year's approval for psilocybin. While this expands access to innovative treatments, it's a highly limited program, with patients currently responsible for out-of-pocket costs and no immediate public funding available. Merchants should monitor this trend as it reflects growing regulatory acceptance of psychedelics in medical contexts, potentially paving the way for future market shifts.

DoubleBlind Mag Those Trump-Shaped Ecstasy Pills Actually Aren't Ecstasy At All PLUS, Amsterdam's last shroom shop, the legality of clinical ketamine, and Eliza Dushku as a psychedelic therapist. Mary Carreón // Editor-in-Chief 07 Sep   TOGETHER WITH Welcome back to

DoubleBlind Mag Is "Gas Station Molly" the Next Big Grey Market Drug? It feels like MDMA, skips the comedown, and it's already on head shop shelves. But is it legal? Patrick McConnell 04 Sep Deep dives and investigations you won't

As FDA approvals for psychedelic therapies draw closer, new Risk Evaluation and Mitigation Strategies (REMS) are highly anticipated. These programs are expected to extend beyond basic safety measures, potentially requiring certified healthcare settings, extensive provider training, patient registries, and specific monitoring periods. The implementation of such comprehensive REMS will profoundly influence operational capacity, provider participation, and overall patient access within the psychedelic therapy market.

DoubleBlind Mag Inside the First Ayahuasca Forum Hosted by Indigenous Peoples 100 Indigenous leaders will gather at the World Ayahuasca Forum to set the terms for ayahuasca's future. Jasmine Virdi 02 Sep Your weekly dose of psychedelic insights and news

Pharmaceutical companies are significantly increasing their Google ad spend on psychedelic-related keywords, primarily promoting regulated treatments like J&J's Spravato, indicating growing mainstream market activity. Concurrently, ARPA-H is funding ibogaine trials, and discussions are advancing regarding potential Medicaid coverage for psychedelic therapies, pointing towards expanding access and regulation for these substances.

DoubleBlind Mag Can Psilocybin Protect Skin Cells From Premature Aging? PLUS Carlos Castaneda, foraging for psilocybin mushrooms, and Resilient Pharmaceuticals. Mary Carreón // Editor-in-Chief 01 Sep   TOGETHER WITH Welcome back to The Drop In, DoubleBlind’s newsletter serving up news,

DoubleBlind Mag Technodelics Promise Psychedelic Healing. Can They Deliver? This Santa Monica lab is using mirrors, strobes, and your own goosebumps — no drugs required. Saga Briggs 28 Aug Deep dives and investigations you won't find anywhere else “Technodelics” Promise

Definium Therapeutics announced positive primary and key secondary endpoint results from its Phase 3 trial of LSD (DT120) for Generalised Anxiety Disorder (GAD). However, expert analysis raises questions about the relatively low single-dose remission and response rates compared to existing GAD treatments, suggesting that future regulatory approvals for psychedelics might benefit from multi-dose protocols. This insight is crucial for businesses monitoring the medical psychedelics landscape, highlighting potential future dosing requirements and efficacy standards that could influence product development and compliance strategies.

DoubleBlind Mag Was Carlos Castaneda Among the First Psychedelic Grifters? Author Carlos Castaneda built a fortune on a fabricated Indigenous lineage. A new biography shows how his blueprint still runs the psychedelic underground. 26 Aug Your weekly dose of psychedelic

DoubleBlind Mag MDMA and the FDA, Take Two PLUS the Psychedelic Seeker's Guide, the World Ayahuasca Forum, and the best films to get trippy to. Mary Carreón // Editor-in-Chief & Jack Gorsline 24 Aug   Welcome back to The Drop

The U.S. Health Resources and Services Administration (HRSA) has concluded its Request for Information (RFI) regarding the delivery of psychedelic therapies, receiving 59 stakeholder comments. This development signals ongoing federal interest in establishing frameworks for future access and could shape the regulatory landscape for psychedelic substances. Merchants should monitor these discussions closely for potential compliance impacts.

Analysis News Pα+ News Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI 20 August 2026 In this Article Workforce Training Delivery in FQHCs, CCBHCs, and Rural Health Clinics Technology-Enabled Scalability, AI The U.S. Health Resources and Services

DoubleBlind Mag   Would You Recognize Abuse in Ceremony? If So, What Do You Do? “The Psychedelic Seeker’s Guide” dives into abusive practitioners and what you should do if you witness abuse in psychedelic settings. Kristina Hunter 19 Aug  

Analysis News News Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C 18 August 2026 Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round at a $190M pre-money valuation, according to documents

Interview Pα+ Interview Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development 18 August 2026 In this Interview From the monoamine hypothesis to plasticity pathways Into humans at the NIH IV ketamine to intranasal esketamine Naysayers Suicidality,

DoubleBlind Mag World Ayahuasca Forum Brings Ancestral Intelligence to Spain PLUS, an interview with an iconic Grateful Dead artist, ayahuasca and loneliness, and Puerto Rico's executive order. Glauber Loures de Assis, PhD, Benjamin De Loenen & Chief Biraci Nixiwaka Yawanawá

DoubleBlind Mag Puerto Rico Makes Moves on Ibogaine, MDMA, and Psilocybin The island's governor just signed an executive order effectively launching a pilot program to research psychedelic therapy. Jack Gorsline 14 Aug Deep dives and investigations you won't find anywhere

News The Psychedelic Practitioner The Psychedelic Practitioner The Psychedelic Practitioner Issue 6: Preparedness (People) 13 August 2026 In this Issue Vitals Interview: Rachel Yehuda Sponsor Viewpoint Practitioner Voices Going Global Research Radar Ethics Corner Welcome to our sixth Issue of

Analysis News News Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application 12 August 2026 Last week, we reported that Resilient Pharmaceuticals (formerly Lykos Therapeutics ) has resubmitted its MDMA for PTSD new drug application (NDA) to the

Analysis News Pα+ Analysis Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD 12 August 2026 In this Article Listen to this Article Trial Design Efficacy Safety This morning, Definium Therapeutics announced positive topline results from

DoubleBlind Mag The Toads Didn't Consent to Being Milked, Sorry Chasing "enlightenment" at the expense of desert toads is not the flex you think it is. Troy Farah 12 Aug Your weekly dose of psychedelic insights and news Is it

DoubleBlind Mag Could Ayahuasca Help Minimize the Loneliness Epidemic? PLUS, ketamine clinics in Beirut, the Horizons conference, and trip-free psychedelics. Mary Carreón // Editor-in-Chief 10 Aug   Welcome back to The Drop In, DoubleBlind’s newsletter serving up news, culture, and

Bulletin Pα+ Bulletin Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly; Turnbull Doubles Down on BOL-148; Compass Talks Indication Expansion, Could VA Help? 7 August 2026 In this Bulletin New: Listen to this Bulletin SAMHSA Convenes Experts

DoubleBlind Mag Inside the Arab World's Psychedelic Revival How four countries are reshaping psychedelic therapy in the SWANA region. Nader Wahba, M.A. 07 Aug Deep dives and investigations you won't find anywhere else How the Arab World Is Forging Its

DoubleBlind Mag A Psychedelic Crime Novel Exploring What Nonfiction Can't Reach Lindsay Kent's psychedelic novel is an argument for fiction as a way of arriving at truth. A.C. Redick 05 Aug Your weekly dose of psychedelic insights and news My

Interview Interview From Sonora to Big Pharma: Kimon de Greef Traces the Strange Rise of 5-MeO-DMT 4 August 2026 K imon de Greef is no stranger to underground economies, having spent years reporting on abalone poaching ( Poacher ) and

DoubleBlind Mag   Horizons and Its Psychedelic Circus Are Back in NYC This Fall PLUS, meeting your soulmate in ceremony, music in psychedelic therapy, and mushrooms in India Mary Carreón // Editor-in-Chief 03 Aug         Welcome back

Puzzle Puzzle Psychedelic Alpha Crossword: Summer 2026 31 July 2026 As we round out an incredibly busy month, we’re sharing something a little more light-hearted: our inaugural Psychedelic Alpha crossword puzzle. Complete the crossword to reveal the red tiles and

DoubleBlind Mag So, the Medicine Introduced You to Your Soulmate. Now What? Meeting your soulmate in ceremony was the mystical part, but how do you make it last afterwards? Suzannah Weiss 31 Jul Deep dives and investigations you won't find

Interview Interview Beyond the Biological Baseline: Dr. Grace Blest-Hopley on Developing Female-Inclusive Psychedelic Frameworks 30 July 2026 In this Interview From Fringes to the Forefront Medical Gaslighting and Widespread Misunderstanding The Hormonal Crossover Emerging Data: Female-Specific Symptom Improvements Psychedelics and

DoubleBlind Mag Is Getting High Off of Banana Peels a Thing? Congress really did try to regulate banana peels. Delilah Friedler 29 Jul Your weekly dose of psychedelic insights and news The Absurd History of Smoking Banana Peels The "hoax"

Analysis News Pα+ News Q1 2026: Oregon Psilocybin Services Update 27 July 2026 Oregon Psilocybin Services (OPS) has now published its first dataset from 2026, with updates summarised in our Oregon Psilocybin Services Tracker . Covering January to March 2026,

DoubleBlind Mag Does Music Matter More Than the Dose in Psychedelic Healing? PLUS, best places to rave in the world, FIFA+psychedelics, and best shows to watch on psychedelics. Mary Carreón // Editor-in-Chief 27 Jul   Welcome back to The Drop

Analysis Pα+ Analysis Psychedelic Funding Update: Q2 2026 24 July 2026 We have updated our Psychedelic Company Financing Tracker to reflect activity in Q2 2026. Quarterly Fundraising Activity in Psychedelics Psychedelic financing activity in the second quarter of 2026 broke

DoubleBlind Mag   The Psilomethoxin Saga Continues A single lab claims to have found the compound that four others couldn’t, and now the church is taking more people to court. Jack Gorsline 24 Jul         Deep dives

Bulletin Pα+ Bulletin Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on the GH-AtaiBeckley Patent Standoff; Field Reacts to FDA’s Guidance; Resilient Readies Resubmission 22 July 2026 In this Bulletin Inside the Lilly-Atai Deal, and a Patent Standoff

DoubleBlind Mag What a Healthy Garden Can Teach You About a Psychedelic Trip 12 rules from the soil for your next journey Leia Friedwoman 22 Jul Your weekly dose of psychedelic insights and news What Permaculture Teaches Us About Psychedelics

Analysis Analysis Q3 2026: Psychedelic Drug Development Pipeline 21 July 2026 This resource is supported by We bring translatable neuroscience expertise to the field of psychotherapeutic research. Drawing on experience from 600+ CNS studies, Syneos Health supports complex drug development

DoubleBlind Mag   Soccer and Psychedelics Have A Very Similar Problem Plus surrogate healing, amanitas, and pharmahuasca gummies. Glauber Loures de Assis, PhD, Mary Carreón // Editor-in-Chief & Reinaldo Lima 20 Jul         Welcome back to The

Analysis Field Notes News Field Notes Field Notes #3: Washington’s Busy Week, and the Biggest Psychedelic Buyout Yet 17 July 2026 W elcome to our third Field Note. As a reminder, Field Notes are timely, candid voice notes from our

DoubleBlind Mag Can Someone Else Drink Ayahuasca to Heal You? In the Shipibo tradition, the answer is yes — and the practice is ancient. Jasmine Virdi 17 Jul Deep dives and investigations you won't find anywhere else Can Someone Else

Analysis News News Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion 16 July 2026 T his morning, Eli Lilly confirmed that it will acquire AtaiBeckley , following rumours circulated in Bloomberg yesterday,

DoubleBlind Mag What's the Deal with the God Molecule? Here's what you need to know about 5-MeO-DMT Anna Wilcox 15 Jul Your weekly dose of psychedelic insights and news 5-MeO-DMT: A Practical Guide to the “God Molecule” This mystical molecule

Harvard Medical School, supported by an $11M NIDA grant, is advancing ibogaine research for Opioid Use Disorder (OUD), aiming for Investigational New Drug (IND) clearance to conduct Phase I and II clinical trials in the U.S. This initiative is distinct from prior noribogaine trials, seeking to study ibogaine itself at higher doses. Securing IND clearance for ibogaine would be a significant milestone for the psychedelic therapeutics landscape.

News News Keeping Up with the Feds: From FDA to HRSA, Washington Backs Psychedelics 13 July 2026 Today has brought a flurry of federal announcements regarding psychedelics, with the FDA (Food and Drug Administration), VA (Department of Veterans Affairs), ARPA-H

Analysis News Pα+ News FDA Issues Final Psychedelics Guidance, Schedules September Hearing on the Future of Psychedelic Therapies 13 July 2026 In this Article Track Changes: Our Line by Line Review of Edits, Additions, and Clarifications Stakeholder Scorecard: The Final

DoubleBlind Mag   One of Psychedelia’s Most Notorious Gurus Is Officially Put on Blast PLUS, stories about datura, the Huni Kuin, and Oregon’s drug policy programs. Mary Carreón // Editor-in-Chief 13 Jul         TOGETHER WITH Welcome back

DoubleBlind Mag The Lizard King Is Calling The origins of the Lizard King mushroom strain is as interesting as Jim Morrison's lyrics for The Doors. Patrick McConnell 08 Jul Your weekly dose of psychedelic insights and news The Origins of

Oregon's Psilocybin Services Program is reportedly facing a proposed fee hike. This development could impact the operational costs for licensed psilocybin service providers and facilitators within the state. Merchants operating or planning to enter the Oregon market should monitor this situation closely for potential changes to their financial outlay and compliance requirements.

Analysis News Pα+ Analysis Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch 7 July 2026 In this Article Efficacy Safety This morning, Compass Pathways shared 26-week data from its second Phase 3 study of COMP360 psilocybin

DoubleBlind Mag   Oregon’s Psilocybin Program Is Feeling a Financial Squeeze PLUS stories on conscious capitalism, full-spectrum mushrooms, healing and lasers, and integration therapy. Mary Carreón // Editor-in-Chief 06 Jul         TOGETHER WITH Welcome back to The

DoubleBlind Mag Could Psychedelics Change Donald Trump? We took a deep dive into the science of psychedelics and how they impact authoritarian attitudes. Peter Holslin 03 Jul Deep dives and investigations you won't find anywhere else What Would Happen If

Analysis News Pα+ Video Video Quarterly Psychedelics Briefing: Q2 2026 3 July 2026 Welcome to our Q2 2026 Quarterly Briefing. Every three months, our Founder & Editor Josh Hardman walks you through major developments from the prior quarter across drug

DoubleBlind Mag   Synthetic Psilocybin Doesn’t Produce the Entourage Effect The effects of full-spectrum psilocybin could have implications for the future of psilocybin-assisted therapy. Marijuana Moment & Ben Adlin 01 Jul           TOGETHER WITH Your weekly

DoubleBlind Mag   Turns Out, Dance Floors and Ceremonies Heal in the Same Way PLUS, a Q&A with Roger Steffens, Zebra fish on Ayahuasca, and how the DEA feels about mushroom spores. Mary Carreón // Editor-in-Chief 29 Jun    

A recent case report on psilocybin for Alzheimer's patients has generated significant media interest but is strictly a research hypothesis, not a treatment recommendation. Merchants should exercise extreme caution regarding claims about psilocybin's therapeutic efficacy for medical conditions, as such statements could lead to compliance issues without robust clinical evidence and regulatory approval. Emphasize that current findings necessitate controlled studies.

This article profiles photographer Roger Steffens, focusing on his historical LSD experiences and artistic career. While the publication includes promotional content for mushroom-related courses, the core article content does not provide any updates on current legislation, compliance requirements, or regulatory changes relevant to merchants in the mushroom and psychedelics industry.

A recent case report on psilocybin for Alzheimer's patients has brought attention to the "complex" legal landscape for psychedelics in Brazil. The treating psychiatrist openly admits to administering psilocybin to hundreds of patients, potentially leveraging his association with a religious group claiming constitutional protections for ceremonial use. This scenario underscores the significant legal ambiguities and varied approaches to psychedelic administration outside formal research, particularly in jurisdictions with evolving or unclear regulations.

Analysis News Pα+ Analysis ‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout 25 June 2026 In this Interview Out by Hour Six? Non-Study Therapy, Past Psychedelic Use The Usual Questions: Expectancy, Unblinding

This article explores the historical trajectory of LSD, from its profound cultural influence in the 1960s counterculture to its eventual prohibition. It details how the 1971 Controlled Substances Act categorized LSD, effectively ending its public availability and initiating a 'psychedelic winter.' While not presenting new legislation, this historical context is vital for understanding the foundational regulatory framework that continues to shape psychedelic compliance today.

Analysis News Pα+ News Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect 22 June 2026 In this Article Trial Design Efficacy Safety This morning, Definium Therapeutics announced positive topline results from its Phase 3 study of

This industry brief from DoubleBlind Mag covers cultural aspects of psychedelics, including fatherhood and the 'psychedelic Boomer' experience. It also features an ad for EdenDirect's 'THC Decoder,' which aims to clarify the complexities of the modern cannabis market by explaining terms like THCa, Delta-9 THC, and various hemp-derived cannabinoids. While primarily focused on cannabis consumer education, this information on market nomenclature and product sourcing offers a peripheral lens for future compliance considerations in the evolving psychedelic landscape.

This DoubleBlind op-ed discusses the nature of 'conspiracy theories' and propaganda, noting how some historically dismissed theories have proven true, shaping public perception. While touching upon the general 'world of psychedelics,' the content does not present any new legislative proposals, regulatory changes, or compliance updates relevant to mushroom or psychedelic businesses. Merchants should recognize this article provides general commentary and not actionable legal or shipping compliance information.

A recent U.S. Presidential Executive Order signals significant federal support for psychedelic research and access, focusing on mental health. Key provisions include $50 million in match-funding for state-level research and expanded 'Right-to-Try' access for Schedule I psychedelics, including psilocybin. This executive action creates new avenues for product development and market entry, particularly for state-level initiatives.

A DoubleBlind Magazine article offers detailed instructions for making psilocybin mushroom tinctures at home. For merchants in the psychedelics space, promoting or linking to content that outlines the synthesis or extraction of federally controlled substances like psilocybin presents significant legal and compliance risks.

Germany has implemented the European Union's first psilocybin compassionate use program, enabling patient access at OVID Clinic Berlin and the Central Institute of Mental Health (CIMH) in Mannheim. While inpatient treatment receives public insurance coverage, both sites are actively pursuing approvals for outpatient modalities. CIMH Mannheim is currently awaiting critical approval from Germany's drug regulator (BfArM) to extend public insurance coverage to outpatient psilocybin therapy, marking a significant step in EU psychedelic regulatory evolution.

DoubleBlind's latest newsletter discusses the globalization of ayahuasca and concerns over the erosion of traditional practices. It also announces a survey exploring the increasing frequency of 5-MeO-DMT administration after ibogaine sessions at retreat centers, which may point to evolving industry practices that warrant monitoring for future regulatory implications.

A growing number of professional athletes are publicly crediting psychedelics like psilocybin and LSD for improved performance, focus, and recovery, despite a lack of scientific validation. This increasing mainstream discourse, alongside denied research applications, signals a developing area that may warrant future regulatory consideration from sports organizations and public health bodies.

This article discusses the ethical debate within the psychedelic community regarding 'pill shaming' of antidepressant users. While not directly related to legislative or compliance changes, it reflects evolving internal community standards and public relations considerations for entities operating in the psychedelic space.

The 2026 psychedelic policy reform push is largely past its peak with most legislatures adjourned, resulting in 17 new psychedelics-related laws enacted across state and federal levels, with a significant portion signed in May. While psilocybin remains prominent through rescheduling laws, ibogaine has emerged as a key focus, with 6 of 25 introduced bills enacted and one nearing passage in New Hampshire. Merchants should review state-specific regulations for these new laws, especially those impacting psilocybin and ibogaine access and distribution.

A recent Field Note from Josh Hardman highlighted key discussions from events in London and the Netherlands concerning the future of psychedelics in Europe. Topics included prospects for ex-U.S. approvals, the role of psychotherapy, and the status of nontraditional access pathways in Germany and Czechia. Merchants should monitor these ongoing discussions as they indicate potential shifts in the European regulatory landscape for psychedelic substances.

While there are no immediate legislative updates, a new article highlights the increasing mainstream presence of 5-MeO-DMT, including expert discussions on its use and harm reduction. Additionally, a survey is being conducted to understand the growing trend of combining 5-MeO-DMT with ibogaine sessions at retreat centers, signaling evolving industry practices that may warrant future regulatory attention.

Australia has eased its psychedelics access regulations, potentially creating new market and research opportunities for regulated substances. In the U.S., Q1 2026 federal lobbying data reveals ongoing efforts to shape psychedelic policy, while new MDMA therapy trials are launching in Maryland and via the VA. Merchants should closely monitor these international and domestic developments for emerging compliance requirements and market shifts.

An open letter from DoubleBlind Magazine calls on clinicians and healthcare providers to acknowledge and integrate psychedelic medicine into women's health. The article highlights that women are already actively using psychedelics for various life stages, often without professional guidance, underscoring a critical need for informed clinical engagement. This insight suggests a growing public adoption and potential future shifts in healthcare practices related to psychedelics, which could indirectly influence regulatory landscapes.

The American Psychiatric Association's (APA) recent annual meeting in San Francisco focused heavily on the growing role of psychedelics in mental healthcare. Discussions revealed a field grappling with the integration of these substances, highlighting both optimism and skepticism among psychiatrists regarding their therapeutic potential. While no immediate regulatory changes for merchants are indicated, these high-level medical conversations are crucial for understanding the evolving landscape that will shape future federal and state compliance requirements for psychedelic substances.

A growing number of products are being marketed as 'psychedelic' or 'microdose' mushrooms but contain no psilocybin, relying instead on adaptogens, stimulants, and other compounds. This trend creates significant compliance risks for merchants due to deceptive labeling and consumer misinformation. Understanding ingredient formulations and clear labeling is crucial for harm reduction and maintaining market integrity.

This DoubleBlind Magazine article explores a father's personal experience using psychedelic mushrooms for self-discovery and to foster deeper presence in parenting. The content is an experiential narrative focusing on individual benefits, rather than providing updates on specific legislation, compliance requirements, or shipping regulations for psychedelic products. Merchants should note this content is cultural/experiential and does not indicate direct regulatory changes or actions.

The FDA has recently undergone significant leadership changes, including the resignation of Commissioner Marty Makary and the appointment of Ex-Usona Institute Chief Medical Officer Mike Davis to the Center for Drug Evaluation and Research. This reshuffle is being analyzed for its potential implications on psychedelic drug development, particularly regarding approval timelines and the competitive race between leading psilocybin developers like Compass Pathways and Usona.

The FDA is a central point of discussion as two major psilocybin developers, Compass Pathways and Usona Institute, accelerate their race towards drug approval. This comes amidst broader regulatory shifts, including leadership changes at the FDA and discussions around ibogaine, signaling a pivotal time for psychedelic market compliance and access.

New York lawmakers are actively supporting a newly amended 'Medical Psilocybin Act' that proposes a state-supervised program for medical psilocybin access. This groundbreaking legislation would allow take-home use for qualifying patients, positioning New York at the forefront of regulated psilocybin access outside clinical settings. The framework, overseen by the NYS Department of Health, emphasizes patient access through stringent rules, education, and close medical supervision.

A recent study published in the Journal of Psychopharmacology investigates the relationship between specific drug use and criminal behavior, suggesting that policing practices may play a significant role in arrest rates rather than the inherent properties of the drugs themselves. This research challenges monolithic views on drug-related crime and could inform future discussions on drug policy.

Reports of abuse and misconduct by facilitators in psychedelic ceremonies are increasingly common, raising significant concerns about participant safety and the ethical standards within the broader psychedelic community. While not directly impacting product compliance, these incidents can damage public perception and potentially lead to calls for stricter oversight or regulatory changes across the entire industry, including companies like MushroomBans.

Major academic institutions, including Johns Hopkins, NYU, Penn, and Yale, have launched a multi-institutional project to educate resident psychiatrists on psychedelic medicine. This grant-funded initiative focuses on crucial aspects like prescriber safety, drug-drug interactions, and equitable access for compounds like psilocybin, MDMA, and ketamine. This effort to standardize medical training for future prescribers signals a significant step towards the mainstream integration of psychedelics into psychiatric care, influencing future compliance and regulatory landscapes for the industry.

DoubleBlind Mag What Happens When You Feel Like Jesus After Taking Psychedelics? Experts explain why some psychedelic trips end in claims of divinity — and when it becomes a problem. Doug Johnson 20 May   TOGETHER WITH Your weekly dose

Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), has publicly shifted her stance, now advocating strongly for further research into psychedelics, including psilocybin for substance use disorders. Her recent presentation at the APA signals growing federal and psychiatric interest in these compounds. This development, coupled with a presidential executive order explicitly calling out ibogaine's therapeutic potential, indicates a significant and accelerating regulatory shift that could impact future market access and compliance standards for merchants.

A growing concern has been identified in the 'legal mushroom' market regarding products designed to mimic psychedelic effects without containing psilocybin. These products often use combinations of adaptogens, stimulants, and functional mushrooms, leading to significant consumer confusion and potential deception. Merchants are urged to prioritize transparent labeling, provide clear ingredient breakdowns, and educate consumers to mitigate harm and ensure compliance with evolving industry standards.

Oregon Psilocybin Services (OPS) has published its fourth and final dataset for 2025, covering July to December. This release offers critical insights into product sales, client motivations, and safety updates within Oregon's regulated psilocybin market. Merchants should review this information to inform compliance strategies and market projections for 2026.

A recent DoubleBlind article critically reviews 'Quiet the Sirens,' a documentary on ketamine-assisted therapy for firefighters in British Columbia. The analysis highlights the complexities and potential oversimplifications in psychedelic advocacy presented through such films. This content is vital for merchants and industry stakeholders to understand the nuances of public messaging and the importance of accurate representation in promoting psychedelic therapies, ensuring ethical and sustainable growth in the sector.

A recent study published in The Journal of Clinical Psychiatry reports promising results for COMP360 psilocybin in treating chronic suicidal ideation and severe depression. The open-label trial found rapid and sustained reductions in symptoms over 12 weeks with no serious adverse events. While this research is a significant step in understanding psilocybin's therapeutic potential, it represents a clinical development and not an immediate change to current psychedelics legislation or merchant compliance requirements.

Psilocybe ochraceocentrata, a psilocybin mushroom from Southern Africa, is gaining popularity among cultivators due to its ease of growth and reported smoother user experience compared to Psilocybe cubensis. While this development is noteworthy for the cultivation community, the article provides no new information regarding specific legislative changes or compliance requirements for this species, which remains subject to existing psilocybin regulations.

President Trump signed an executive order on April 18th, 2026, directing federal agencies to expedite psychedelic research and patient access. This order includes measures such as ARPA-H match-funding for state research, FDA priority vouchers for psychedelic candidates, and earlier DEA scheduling reviews. Merchants should note the expansion of 'Right to Try' pathways to include investigational Schedule I psychedelics, signaling a federal push to streamline development and potentially alter the regulatory environment.

The legal mushroom market is seeing a surge in products, marketed as 'psychedelic' or 'microdose,' that contain no actual psilocybin. These products often blend adaptogens, stimulants, and functional mushrooms to mimic desired effects, creating significant consumer confusion and potential harm. For legitimate merchants, understanding formulation strategies and promoting clear labeling is crucial to maintain trust and avoid association with deceptive practices.

This DoubleBlind Magazine article offers a guide for consumer safety and harm reduction practices while using psychedelics in natural settings. It features personal anecdotes and expert advice focused on individual user experiences. The content does not contain any information regarding new or proposed legislation, shipping regulations, or other compliance mandates directly impacting merchants in the psychedelics industry.

A groundbreaking study published in JAMA Network Open reports that a single dose of psilocybin combined with psychotherapy significantly reduced cocaine use in participants, representing the first successful trial for this condition. This robust clinical evidence strengthens the scientific foundation for psilocybin's therapeutic applications, indicating a continued trend toward medical legitimization and potential future changes in regulatory frameworks for psychedelics. Merchants should monitor these developments as they may influence future market demand and legislative compliance requirements related to therapeutic access.

The psychedelics industry is actively responding to a recent federal executive order, with many welcoming its potential to accelerate access to therapies. Advocates are specifically urging the FDA to prioritize MDMA-assisted therapy for PTSD, pushing for fast-tracked review of programs with completed Phase 3 trials. Merchants should closely monitor these federal policy shifts and FDA actions as they will significantly influence the regulatory landscape and market access for therapeutic psychedelics.

The Shulgin Foundation has opened a never-before-seen archive on MDMA to the public in Berkeley, featuring primary sources including a letter from Ann Shulgin to President Ronald Reagan advocating for its therapeutic value in 1984. While this event does not impact current compliance or shipping regulations, it offers valuable historical context on psychedelic advocacy and regulatory challenges that may inform future policy discussions.

Recent observations indicate a significant increase in Americans engaging in self-guided microdosing, leading to a burgeoning demand for qualified microdosing facilitators. This growing trend signals the professionalization of psychedelic support services, which could precede future regulatory discussions concerning psychedelic guidance and service provision.

President Donald Trump recently signed a psychedelics-focused Executive Order, a development significantly influenced by W. Bryan Hubbard of Americans for Ibogaine. This executive action creates a notable political opening for ibogaine and suggests a potential future pathway for broader psychedelics accessibility and treatment models. MushroomBans advises merchants to closely track federal legislative and regulatory movements following this order, as it may shape the future landscape for compliant psychedelics businesses.

This DoubleBlind Magazine article explores the personal and social aspects of mushroom use, emphasizing friendship and connection. It does not contain any information related to psychedelic legislation, compliance updates, shipping restrictions, or regulatory changes relevant to merchants in the mushroom and psychedelics industry.

Tech entrepreneur Bryan Johnson's public 5-MeO-DMT and psilocybin experiments, including one at a licensed Oregon facility, elevate the mainstream visibility of psychedelics. While the article doesn't report new legislation, these high-profile events may influence future regulatory discussions and public perception around the use and distribution of these substances. Merchants should monitor these trends for potential shifts in the compliance landscape.

The rapid expansion of the psychedelic industry is drawing attention to critical social equity issues, specifically the exclusion of traditional knowledge holders and key community voices. While this content does not present immediate regulatory changes, it highlights evolving industry dialogues that could inform future ethical standards, social responsibility expectations, and potentially influence legislative frameworks regarding inclusivity.

DoubleBlind Mag Rick Doblin Speaks with Protesters About Gaza and MAPS Israel Plus, executive order details, FDA guidelines for psychedelic research, and psilocybin for weight loss. Mary Carreón // Editor-in-Chief & Jack Gorsline 27 Apr TOGETHER WITH Welcome back to

The FDA has awarded three Commissioner’s National Priority Vouchers (CNPVs) to Compass Pathways (psilocybin for TRD), Usona Institute (psilocybin for MDD), and Otsuka/Transcend (methylone for PTSD). These vouchers are designed to significantly reduce the new drug application (NDA) review period to just one to two months, signaling an accelerated path to market for these substances. This move underscores the FDA's commitment to advancing psychedelic therapies, with further guidance for sponsors expected imminently.

U.S. President Donald Trump has signed an executive order titled 'Accelerating Medical Treatments for Serious Mental Illness,' directing federal agencies to streamline FDA approval for 'breakthrough' psychedelic medicines. This order prioritizes ibogaine research for veterans' mental health and substance use, backed by a $50 million federal initiative. Merchants in the psychedelic space should monitor developments as this signifies a major federal push to accelerate access and potentially reduce future regulatory barriers.

President Trump recently signed an executive order aimed at accelerating psychedelic research and access. This federal action signals increased government interest and potential support for the psychedelics field, though specific direct legislative impacts are yet to be determined. Merchants should monitor the implications for future legislation and market expansion as research progresses and access measures are developed.

DoubleBlind Mag The Dark Side of Psychedelic Healing, According to Erica Rex A conversation on trauma, power, and the risks of trusting systems meant to heal A.C. Redick 22 Apr TOGETHER WITH Your weekly dose of psychedelic insights and news

The burgeoning legal mushroom market is rife with products falsely claiming psychedelic properties, often lacking actual psilocybin. Merchants are urged to prioritize accurate labeling and transparent product descriptions to ensure compliance, differentiate genuine psilocybin products, and uphold consumer trust amidst a mix of adaptogens and mimics.

President Trump has signed an executive order intended to accelerate access to psychedelics, provide funding for state-backed research, and enhance public-private collaboration. This significant federal action could create new market opportunities and necessitate monitoring for upcoming regulatory changes relevant to merchants in the psychedelics space.

President Trump has signed an Executive Order to accelerate psychedelic research and expand access, directing federal agencies to reduce bureaucratic barriers and providing match-funding for state-led studies. While not an immediate change for current compliance, this federal initiative significantly advances the legal and scientific pathways for psychedelics, setting the stage for potential future medical and therapeutic markets. MushroomBans advises merchants to monitor these developments closely, as increased research and streamlined processes could precede broader regulatory shifts.

An article from DoubleBlind Magazine details a growing subculture's claim that DMT combined with a red laser can reveal a 'code of reality.' While interesting for the psychedelic community, this report focuses on anecdotal user experiences and does not present any new legislative, regulatory, or shipping compliance concerns for mushroom and psychedelic merchants at this time.

High-profile ibogaine advocates, including Rick Perry and Bryan Hubbard, are leveraging platforms like the Joe Rogan Experience to lobby for federal attention on ibogaine. While this signals sustained efforts to advance psychedelic policy, their previous $50M Texas Ibogaine Initiative ultimately failed, underscoring the significant challenges in enacting state-level psychedelic legislation. Businesses should monitor federal discussions and be aware of the complex legislative landscape.

The psychedelic industry saw a slight decrease in Q1 2026 funding, totaling $348M across 11 events, reflecting a potentially cautious investment environment. A substantial portion of this capital flowed to Compass Pathways, which is actively pursuing an FDA New Drug Application for psilocybin for treatment-resistant depression following positive Phase 3 readouts. This sustained investment in drug development and regulatory pathways by major players suggests ongoing efforts to bring psychedelic substances to market, which will likely shape future compliance landscapes for merchants.

DoubleBlind Magazine has launched a new coffee table book covering psychedelic journeying, including dosage and integration guidance. The publication also highlighted the prevalence of psychedelic culture at major electronic music festivals globally. While not directly related to new legislation, this content reflects broader trends in psychedelic interest and public engagement.

The Cambridge Psychedelic Research Group (CPRG), operating under a Home Office licence since 2024, is actively developing scalable psychedelic-assisted treatments for integration into the UK's National Health Service (NHS). This initiative marks a significant step in establishing a legal framework for medical psychedelics in the East of England and could influence future regulatory landscapes for psychedelic-based products. Merchants should monitor these advancements as they contribute to the broader legitimization and potential medical market for psychedelics.

DoubleBlind Magazine features a screenplay, 'The Faerie Rings,' that symbolically addresses psychedelic prohibition and the quest for cognitive liberty. While not reporting on specific legislative changes, this cultural piece reflects ongoing societal discussions that can influence future policy and public perception regarding psychedelics. Merchants are encouraged to stay aware of evolving cultural narratives surrounding regulation.

This DoubleBlind Magazine article explores anecdotal evidence and scientific speculation regarding telepathic experiences reported during psychedelic use, featuring personal accounts and insights from a psychedelic psychotherapist. From a regulatory and compliance perspective for MushroomBans merchants, this content does not present any actionable alerts, changes in legislation, shipping restrictions, or sales regulations related to mushrooms and psychedelics.

This report from Psychedelic Alpha details the significant intellectual property (IP) activity in the psychedelic space during 2025, tracking nearly 1,500 U.S. patents and applications, including neuroplastogens. It identifies top filers like CaaMTech, GH Research, and Compass Pathways, indicating a maturing IP landscape.

The latest issue of 'The Psychedelic Practitioner' focuses on 'Integration,' the crucial post-psychedelic journey stage, featuring insights from leading experts like Dr. Ros Watts. While this content does not directly detail legislative or compliance changes, understanding evolving best practices for psychedelic integration is important. Such discussions help anticipate potential shifts in future regulatory frameworks and ethical guidelines within the expanding psychedelics industry, which could eventually impact merchants.

This article advocates for a paradigm shift in psychedelic access, moving beyond the current focus on clinical models towards community-based frameworks. It argues that while scientific validation is crucial, exclusive clinical pathways limit accessibility and fail to address how most people already use psychedelics. Merchants should monitor this evolving advocacy landscape, as successful community integration could necessitate different regulatory and compliance strategies for broader public access beyond medical settings.

Texas announced significant progress on its $50 million ibogaine research program, focusing on in-state medical teams after external proposals fell short. This critical development coincides with Mississippi's new HB314, which mandates its research consortium to coordinate with and use the same drug developer as a lead consortium in another state, effectively tethering it to the Texas-anchored network.

This article from DoubleBlind's 'The Drop In' newsletter highlights a San Francisco conference on psychedelic culture and emphasizes the importance of home cultivation. While it covers general industry trends and cultural events, it does not contain specific updates on legislation, shipping restrictions, or compliance changes relevant to merchants at this time.

DoubleBlind Magazine argues that true psychedelic reform must include the right to home cultivation, challenging current movements that may inadvertently favor corporations and perpetuate prohibition. This perspective is critical for merchants to understand the ongoing legislative and advocacy landscape, as the inclusion or exclusion of home grow provisions will significantly shape future market dynamics and consumer access.

This Q1 2026 briefing provides a comprehensive overview of critical regulatory and policy developments impacting the psychedelics industry. Key updates include FDA actions, progress on various state and federal bills, and advancements in state psychedelics programs, notably 'breaking news' regarding Texas' ibogaine initiative. Merchants should review these multi-jurisdictional insights to proactively navigate evolving compliance landscapes and prepare for anticipated Q2 policy shifts.

This DoubleBlind Mag article explores the historical evolution of psychedelic gatherings, from early music festivals and 'Love-Ins' to Ken Kesey's Acid Tests. While it offers cultural context on the psychedelic movement, it does not contain specific legislative updates, compliance information, or regulatory changes pertaining to mushroom or psychedelic businesses relevant to our merchants.

DoubleBlind's 'The Drop In' newsletter spotlights a plant medicine and spirituality gathering in the Bay Area over Easter weekend, offering an alternative spiritual conversation. The newsletter also features MycoMeditations' comprehensive guide to psychedelic healing, outlining options like retreats, clinics, and microdosing, but contains no specific legislative or compliance updates.

An interview with Dr. Gitte Moos Knudsen details current neurobiological understanding of classic psychedelics, emphasizing the role of the 5-HT2A receptor, neuroplasticity, and synaptic density changes. While not directly legislative, this foundational research is critical for developing safe and effective therapeutic applications, potentially influencing future regulatory frameworks and product standards for psychedelic compounds.

A recent article details the groundbreaking psychedelic research of Robin Carhart-Harris, providing a historical look at his journey. It notes that in the mid-1990s, psychedelics were classified as Class A, Schedule I substances under the UK's Misuse of Drugs Act. While not a new legislative update, this provides historical context on drug regulation impacting early psychedelic studies.

The highly anticipated German EPIsoDE study on psilocybin for Treatment-Resistant Depression (TRD) has been published, revealing 'modest results' compared to its ambitious initial goals. While not a direct regulatory change, these findings contribute to the evolving scientific discourse on psilocybin's therapeutic efficacy. Merchants should stay informed on such research, as it influences public perception, potential medical guidelines, and the long-term regulatory trajectory for psilocybin-based products.

Japanese pharmaceutical company Otsuka is acquiring Transcend Therapeutics, a developer of methylone (an MDMA analog), in a $1.23 billion deal. Transcend's lead candidate, TSND-201 for PTSD, is progressing to Phase 3 clinical trials, marking a significant advancement for a psychedelic-analog-based therapy within the pharmaceutical pipeline. This acquisition signals increasing mainstream investment and potential future regulatory pathways for controlled substances related to the psychedelics market.

A high-stakes power shift is unfolding at Lykos Therapeutics, with a billionaire launching a $100 million bid to take control. This move is anticipated to bring MAPS founder Rick Doblin back into a pivotal role for integrating MDMA therapy into mainstream medicine, potentially altering the regulatory and commercial landscape. Merchants in the psychedelics space should closely monitor these corporate dynamics for their long-term impact on market access and future compliance standards.

This DoubleBlind Mag article discusses 'set' and 'setting' for psychedelic journeys, focusing on creating a comfortable environment for users. While offering insights into personal psychedelic experiences, it provides no information pertinent to current or proposed legislation, compliance requirements, or shipping regulations for businesses operating within the psychedelics niche.

This interview with Dr. Brian Barnett delves into the future of scaling medical psychedelic treatments, addressing psychiatrist perceptions, the role of ketamine, and critical challenges like reimbursement models (RVUs). While not focused on immediate legislation, it offers valuable insight into the evolving regulatory and financial frameworks that will shape the accessibility and delivery of approved psychedelic therapies.

DoubleBlind's latest newsletter, 'The Drop In,' covers cultural and experiential aspects of psychedelics, including an interview with comedian Shane Mauss about LSD and other stories on psilocybin for Lyme disease. This article does not contain any updates regarding new legislation, shipping restrictions, or compliance changes relevant to mushroom and psychedelic merchants.

Federal complaints allege illegal lobbying and misuse of internal congressional data by former lawmakers, Mimi Walters and Kyrsten Sinema, in connection with psychedelic policy efforts. These controversies are drawing intense scrutiny to lobbying practices within the psychedelic industry. Businesses should monitor these developments as increased oversight could influence future legislative and regulatory landscapes.

Despite reported chaos among federal agencies and infighting within the psychedelic advocacy field, stakeholders maintain quiet confidence that FDA approvals for psychedelic candidates will proceed. While FDA reviews are expected to remain on track, broader psychedelic policy reforms may face headwinds during the election year, potentially chilling legislative progress. Advocacy specifically for ibogaine is also noted as becoming a distinct focus area.

This article explores the historical and ongoing influence of psychedelics on musicians and their creative processes, highlighting artists from the 1960s to contemporary times. It details how these substances have shaped songwriting and artistic expression across various genres. This content does not contain any updates regarding legislation, compliance changes, or regulatory actions relevant to the sale or distribution of psychedelics or mushrooms.

Dr. Charles Nemeroff, co-director of a major psychedelic research center in Texas, is actively securing significant funding for his studies into substances like ibogaine. Crucially for our merchants, Nemeroff has expressed explicit concerns regarding non-medical access models, specifically mentioning Oregon's approach. This strong stance from a leading researcher signals potential future scrutiny or regulatory shifts for non-medical psychedelic markets.

This industry update highlights ongoing discussions regarding the efficacy and precise definition of 'microdosing,' particularly concerning 'subperceptual' doses, which could influence product labeling and marketing claims. It also touches upon the evolving landscape of legal psychedelic therapy, indicating an expanding market for related services. Merchants should monitor these discussions to ensure compliance with future regulatory shifts and accurately position their products.

A recent pilot study at Johns Hopkins University is exploring the efficacy of psilocybin in treating chronic Lyme disease symptoms. While this research does not directly change current legal or shipping regulations, positive findings could bolster arguments for wider medical legalization and rescheduling of psilocybin in the future. Merchants should monitor such studies as they contribute to the evolving landscape of psychedelics acceptance.

The latest industry bulletin predominantly covers clinical trial advancements for psychedelic compounds like DMT analogs and psilocybin. Crucially for merchants, the report includes a dedicated, albeit unelaborated, category for 'New State Bills.' This signals a continued need for vigilance regarding emerging state-level legislation that could impact the sale and distribution of psychedelic-related products.

This article provides a high-level overview of the evolving global landscape for psychedelic-assisted therapy. It notes a significant shift from historical prohibition towards increasing legalization worldwide, driven by renewed scientific and cultural acceptance. While not detailing specific new legislation, it signals a growing international market and regulatory environment for psychedelic-related businesses.

AtaiBeckley is in advanced discussions to partner its intranasal 5-MeO-DMT (BPL-003) drug candidate, targeting treatment-resistant depression. This development signals continued significant pharmaceutical investment and interest in psychedelic-based medicines. While important for the medical sector, this news pertains to clinical drug development and does not introduce new legislative or compliance requirements for merchants at this time.

Four states are advancing legislation to prepare for FDA-approved psilocybin therapies. These bills are specifically tailored for patented pharmaceutical psilocybin, differentiating them from general legalization efforts. This focus could define a future market where pharmaceutical products are prioritized over natural psilocybin, warranting close attention from merchants regarding potential market access and product compliance.

Over twenty new psychedelic-related bills have been introduced across numerous U.S. states in February 2026, with many others advancing through legislative processes. These proposed laws cover a broad spectrum, including rescheduling trigger laws, research initiatives, and veteran access programs. Merchants must closely monitor these developments for potential impacts on cultivation, processing, and distribution across various states.

February 2026 saw significant psychedelic policy activity across U.S. state legislatures, with approximately twenty new bills introduced and several others advancing through committee and floor votes. The legislative efforts cover a broad spectrum, including rescheduling trigger laws, ibogaine research initiatives, and veteran-focused access programs, collectively impacting nearly one hundred tracked bills.

This article from DoubleBlind Magazine critiques the prevalent over-hyping of preliminary psychedelic research studies, warning it risks undermining scientific integrity and the broader movement for legalization and decriminalization. It urges stakeholders, including media and researchers, to adopt more responsible communication practices. For MushroomBans merchants, this insight underscores the importance of measured and accurate information dissemination to maintain public trust and support legislative advancements.

An article highlights the rise of custom ketamine spoons as a cultural phenomenon at a music festival in British Columbia, Canada. While ketamine is within the broader psychedelics category, this report focuses on recreational accessory trends and does not indicate any new legislative changes or compliance issues directly impacting mushroom or psychedelic merchants. There are no proposed regulations, shipping restrictions, or legal shifts relevant to our audience.

This article shares personal stories of adult children introducing psilocybin to their elderly parents, highlighting perceived benefits for end-of-life anxiety and depression. While these anecdotes reflect growing cultural acceptance and discussion around psilocybin, there are no immediate legislative or compliance updates for merchants. MushroomBans advises maintaining strict adherence to current state and federal regulations regarding the sale and distribution of psychedelic substances.

The psychedelic tourism industry is experiencing rapid global growth, with hundreds of retreat options available. This expansion is often characterized by 'Wild West-style' operations, highlighting substantial safety and ethical compliance risks for both participants and operators. Merchants involved in or considering this sector must be acutely aware of potential legal liabilities and reputational damage from operating in a largely unregulated market.

This industry analysis from Psychedelic Alpha identifies critical unanswered questions across psychedelic drug development and policy, including public opinion, political considerations, and the future of non-traditional access pathways. Merchants should monitor these discussions as they directly inform potential legislative shifts and future market opportunities or restrictions, providing a strategic overview for proactive compliance planning.

This DoubleBlind newsletter update covers emerging scientific insights into ayahuasca experience prediction and general cultural interest in psychedelics, including how to engage parents with mushrooms. While not a direct compliance alert, it highlights the evolving public perception and scientific understanding surrounding these substances, which can indirectly influence future regulatory landscapes.

DoubleBlind Magazine features Brian Chambers and The Chambers Project, highlighting his extensive collection and preservation efforts of psychedelic art. This article focuses on the cultural aspect of psychedelics through art and does not contain any information regarding new legislation, shipping restrictions, or compliance requirements for merchants in the mushroom or psychedelic space. No direct action or changes are required for your business operations based on this content.

Yale University, through its ENACT Research Collaborative, is actively conducting psilocybin clinical trials for Obsessive Compulsive Disorder (OCD), led by Dr. Terence Ching. This research, including a recently concluded randomized placebo-controlled trial, explores potential mechanisms and integration with evidence-based therapies. While not a direct regulatory change, these ongoing scientific developments signal long-term trends that could influence future psychedelic policy and medical applications.

This DoubleBlind Magazine article explores the historical presence of psychoactive plants in ancient scriptures, like the Bible. While interesting from a cultural and historical perspective, it does not contain any information pertaining to current legislation, compliance requirements, or shipping regulations for mushroom or psychedelic businesses.

New legislative activity is emerging at both state and federal levels. Connecticut SB00191 proposes modifications to its psychedelic-assisted therapy program, while West Virginia SB906 introduces a trigger law. Furthermore, Congressional appropriations bills now include language on psychedelic therapy, indicating increased federal attention. Merchants should closely track these developments as they may lead to new compliance requirements and market shifts.

The article briefly mentions "the dangers of AI around mushroom science" as a topic of interest. While no specific regulations or legislative actions are detailed, this signals a potential emerging area of concern for compliance. Businesses should monitor future developments regarding AI's role in the industry, particularly concerning data integrity, research ethics, and information accuracy.

A recent DoubleBlind article discusses the emerging therapeutic application of psychedelics to treat 'eco-anxiety' and climate grief. While this development does not immediately impact current legislation or shipping compliance, it reflects a growing scientific and public interest in the mental health benefits of psychedelics. Merchants should monitor such discussions as they contribute to the broader narrative that could shape future regulatory landscapes and market acceptance.

Experts are interpreting Compass Pathways' recent Phase 3 psilocybin data for treatment-resistant depression as a strong indicator that FDA approval is now a matter of 'when, not if.' This development, if realized, would mark a significant federal milestone for psilocybin, potentially influencing future regulatory frameworks and market access for psychedelic compounds.

This report provides an overview of the psychedelic drug development pipeline for Q1 2026, detailing progress in clinical trials across various molecules and indications. While directly focused on pharmaceutical research, it offers insight into the evolving medical landscape for psychedelics, which could influence future regulatory discussions impacting the broader market.

This piece discusses the emerging societal conversation around using psychedelics for end-of-life care, highlighting a philosophical shift rather than new legislative mandates. Additionally, it features an advertisement for 'Psilly Goose,' a functional beverage containing Kanna, Lion's Mane (a mushroom), and hemp-derived Delta-9 THC. This advertisement serves as a reminder for merchants to monitor the evolving landscape of novel cannabinoid and functional mushroom products, and their varying state-specific compliance requirements.

Compass Pathways announced further positive Phase 3 clinical trial data for its psilocybin-based therapies, including topline results for COMP006 and 26-week data from COMP005. This development signifies continued progress in bringing psychedelic compounds through the medical regulatory pathway. For merchants, these advancements underscore the growing legitimacy and potential for broader market access and future regulatory changes for psilocybin.

As the psychedelics industry moves towards the mainstream, a critical discussion has emerged regarding leadership and the qualifications of those guiding this expansion. This conversation, while not immediately impacting current regulations, signals an evolving emphasis on professional standards and ethical frameworks within the industry. Merchants should monitor these discussions as they could influence future compliance requirements and industry best practices.